New drug cocktail shows promise for tough prostate cancer
NCT ID NCT03934840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested a combination of three drugs—carboplatin, cabazitaxel, and abiraterone—in 61 men with high-volume metastatic prostate cancer that still responds to hormone therapy. The goal was to see how many men had no cancer growth after one year. The study also tracked side effects and how long the cancer stayed under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carboplatin, cabazitaxel, abiraterone, and prednisone
What this could lead to
If successful, this combination could offer a new treatment option to delay cancer progression in men with advanced prostate cancer.
What could go wrong
This is a small, early-phase trial with only 61 participants. The combination may cause significant side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169, United States
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Thomas Jeferson University
Philadelphia, Pennsylvania, 19107, United States
-
Tulane University
New Orleans, Louisiana, 70112, United States
-
University of Chicago
Chicago, Illinois, 60637, United States